31.10.2017 • NewsDede WillamsClariantwhite tale

White Tale Tells Clariant its Terms

(c) Clariant
(c) Clariant

Following Swiss speciality chemicals producer Clariant’s decision last week to back away from the $20 bn merger with Huntsman announced in May –  citing uncertainty over gaining the required approval by two-thirds of its shareholders – activist investor White Tale has launched a drive to reshape the company according to its own vision.

In a letter to management dated Oct. 30, the acquisition vehicle of the funds 40 North and Corvex, now Clariant’s biggest shareholder with 20% of capital, unveiled its targets, as a “long-term investor,” to ensure the chemical producer’s “success.” White Tale said its immediate priority is to have three of its representatives seated on the board of directors, while hinting that it will solicit support for this from other shareholders.

In the interest of restoring Clariant’s “credibility,” the investor also has called for the appointment of an independent financial advisor not involved in the Huntsman transaction to undertake a “thorough review of all strategic advantages without prejudging the outcome and without self-interested pre-conditions.”

As the Swiss company’s largest shareholder, White Tale said it will take responsibility to see its conditions fulfilled, and if Clariant’s management does not agree will push for an extraordinary general meeting. The funds stressed again that a primary goal continues to be divestment of the spun-off Plastics and Coatings business, with the proceeds reinvested in “pure-play” specialty chemicals businesses.

Without commenting on the proposals, Clariant said its supervisory board will discuss the “requests” at its next meeting. It added that it has also offered to outline its own growth strategy for White Tale, listen to its plans and discuss “appropriate concrete ways forward.” The company said it also has invited the investor to hold further talks, while continuing the ongoing dialog with all “shareholders that have shown long-term interest in the company.”

Commenting on the exchange of communications, analysts at investment broker Bernstein said they expect an independent review would show that the merger with Huntsman “did not make strategic sense.” At the same time, they noted that White Tale would need the support of 50% of share capital to remove Clariant’s management. According to news agencies, CEO Hariolf Kottmann has indicated he has no plans to step down.      

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.